Du Runsen, Shang Fangjian, Chen Xin, Jiang Xia, Liu Bo, Zhao Zengren
Breast and Thyroid Center, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Department of General Surgery, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Gland Surg. 2024 Nov 30;13(11):2023-2042. doi: 10.21037/gs-24-287. Epub 2024 Nov 26.
The advancement of early detection and treatment has brought about a significant concern for male breast cancer (MBC) survivors-the emergence of a second primary malignancy (SPM) poses a grave threat to their lives. Among them, second primary prostate cancer (spPCa) holds particular significance. This study aimed to investigate the impact of spPCa on the prognosis of MBC patients.
We performed a retrospective analysis using information from the Surveillance, Epidemiology, and End Results (SEER) database to investigate individuals diagnosed with MBC who also experienced an SPM between 2000 and 2020. Propensity score matching (PSM) was employed to balance the baseline characteristics of individuals with spPCa and those with second primary non-prostate cancer (non-PCa). The impact of spPCa on participant survival was assessed using the Kaplan-Meier method. Furthermore, two nomograms were developed, based on univariate and multifactor Cox regression analyses, to predict overall survival (OS) and cancer-specific survival (CSS). The capacity of the nomograms was evaluated using the concordance index (C-index), calibration curve, receiver operating characteristic (ROC) analysis, and decision curve analysis (DCA). Additionally, a risk stratification system was devised, taking into account the cumulative score of each patient in the nomogram.
This study enrolled a total of 885 MBC patients who experienced an SPM, of which 265 (29.9%) were diagnosed with spPCa. Through PSM, 257 pairs of eligible participants were selected. Survival analysis revealed that patients with prostate cancer (PCa) as an SPM have longer OS and CSS compared to those with other types of cancer as an SPM. The participants were randomly divided into a training set and a validation set in a ratio of 7:3. The Cox proportional hazards model was utilized to assess the risk factors associated with survival outcomes. Two nomograms were developed to forecast the 3-, 5-, 8-, and 10-year OS and CSS of male patients who had breast cancer and SPM. The two nomograms exhibited excellent performance in terms of the C-index, ROC curves, calibration plots, and DCA curves, demonstrating their exceptional clinical discriminative ability and predictive utility. In the risk stratification system predicated on the total score of the nomogram, patients deemed high-risk exhibited diminished OS and CSS. Additionally, we created user-friendly web applications to enhance the accessibility of the nomogram in clinical practices, which can be accessed at https://mbcpre.shinyapps.io/DynNomapp_OS/ for OS and https://mbcpre.shinyapps.io/DynNomapp_CSS/ for CSS.
MBC patients with spPCa exhibit a more favorable prognosis than those with other SPMs. The two nomograms we constructed could accurately forecast the OS and CSS for MBC patients with spPCa. Patients whose nomograms are stratified as high-risk should gain additional attention. Our nomograms may aid clinicians in personalizing treatment strategies and supporting clinical decisions.
早期检测和治疗水平的提高引发了男性乳腺癌(MBC)幸存者的一个重大担忧——第二原发性恶性肿瘤(SPM)的出现对他们的生命构成了严重威胁。其中,第二原发性前列腺癌(spPCa)具有特殊意义。本研究旨在探讨spPCa对MBC患者预后的影响。
我们利用监测、流行病学和最终结果(SEER)数据库中的信息进行回顾性分析,以调查2000年至2020年间被诊断为MBC且同时发生SPM的个体。采用倾向评分匹配(PSM)来平衡spPCa患者和第二原发性非前列腺癌(非PCa)患者的基线特征。使用Kaplan-Meier方法评估spPCa对参与者生存的影响。此外,基于单因素和多因素Cox回归分析,开发了两个列线图,以预测总生存期(OS)和癌症特异性生存期(CSS)。使用一致性指数(C-index)、校准曲线、受试者操作特征(ROC)分析和决策曲线分析(DCA)评估列线图的性能。此外,设计了一个风险分层系统,考虑每个患者在列线图中的累积得分。
本研究共纳入885例发生SPM的MBC患者,其中265例(29.9%)被诊断为spPCa。通过PSM,选择了257对符合条件的参与者。生存分析显示,与以其他类型癌症作为SPM的患者相比,以前列腺癌(PCa)作为SPM的患者具有更长的OS和CSS。参与者按7:3的比例随机分为训练集和验证集。使用Cox比例风险模型评估与生存结果相关的危险因素。开发了两个列线图,以预测患有乳腺癌和SPM的男性患者的3年、5年、8年和10年OS和CSS。这两个列线图在C-index、ROC曲线、校准图和DCA曲线方面表现出色,证明了它们卓越的临床鉴别能力和预测效用。在基于列线图总分的风险分层系统中,被认为是高风险的患者OS和CSS降低。此外,我们创建了用户友好的网络应用程序,以提高列线图在临床实践中的可及性,可通过https://mbcpre.shinyapps.io/DynNomapp_OS/访问OS相关的列线图,通过https://mbcpre.shinyapps.io/DynNomapp_CSS/访问CSS相关的列线图。
患有spPCa的MBC患者比患有其他SPM的患者表现出更有利的预后。我们构建的两个列线图可以准确预测患有spPCa的MBC患者的OS和CSS。列线图分层为高风险的患者应得到额外关注。我们的列线图可能有助于临床医生制定个性化的治疗策略并支持临床决策。